Background: Legionnaires' disease (LD) is an important cause of community-acquired pneumonia with high mortality rates in the most severe cases.
Introduction
Legionnaires' disease (LD) is an important cause of communityacquired pneumonia, resulting from the inhalation of aerosols containing Legionella spp. and subsequent lung infection. Nearly 7000 cases of LD are reported each year in Europe. 1 Large outbreaks of LD have been associated with contaminated cooling towers, hot and cold water systems and whirlpool spas. 2 LD ranks among the three most common causes of severe community-acquired pneumonia leading to ICU admission, 3, 4 and carries a mortality rate that ranges from 20% to 33%. 5, 6 Risk factors for mortality typically include an older age, tobacco use, chronic cardiac or respiratory diseases, diabetes, chronic alcohol intoxication, cancer and V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
immunosuppression. 2 The administration in a timely fashion of an appropriate antibiotic targeting Legionella spp. is a recognized prognosis factor. 4, 5, [7] [8] [9] For the most severe presentations requiring ICU admission, recommended antibiotic regimens include a fluoroquinolone, either in monotherapy or combined with a macrolide. [10] [11] [12] [13] Recent descriptions of fluoroquinolone resistance in Legionella spp. argue for the use of combination therapy for treating severe LD. 14, 15 However, the optimal antimicrobial regimen for treating severe LD remains controversial and the level of evidence is weak. [10] [11] [12] Moreover, the current emergence of MDR bacteria encourages the restriction of antibiotic use, especially regarding the prescription of fluoroquinolones. 16, 17 While prospective randomized controlled trials would ideally be required to determine which class of antibiotic is superior to others or whether a combination therapy regimen provides significant clinical benefit over monotherapy, running such trials would be challenging because of difficulties concerning inclusion of the appropriate number of patients, together with limitations related to the prospective inclusion of patients having an acute illness but no confirmed microbiological diagnosis.
We thus performed a multicentre retrospective study to assess the impact of the antibiotic strategy on outcomes in a large cohort of patients with LD requiring ICU admission. The main objective of this study was to evaluate the outcome of patients admitted to the ICU for severe LD according to the antimicrobial strategy used, as follows: (i) fluoroquinolone-based versus non-fluoroquinolonebased therapy; and (ii) monotherapy versus combination therapy. 
Patients and methods

Ethics
Patients
This is a retrospective observational cohort study of adult patients with LD admitted to 10 French ICUs between January 2005 and June 2015. Eligible patients were aged 18 years and required ICU admission for severe LD, defined as an acute illness with clinical (i.e. fever, cough, sputum production, shortness of breath or acute respiratory failure) and radiographic (i.e. new pulmonary infiltrate) signs of pneumonia, with at least one of the following laboratory criteria for Legionella spp. infection (adapted from criteria for confirmed or probable cases as defined by the ECDC 1 ): (i) detection of urinary soluble antigens of Legionella pneumophila serogroup 1; (ii) isolation of Legionella spp. from any respiratory sample culture; (iii) 4-fold rise in serum antibody titres to at least 1:128; or (iv) detection of L. pneumophila DNA by a PCR assay from any respiratory sample. Patients with nosocomial LD, missing data or without anti-Legionella antimicrobial therapy during the first 48 h following ICU admission (i.e. 2 calendar days) were excluded from analysis. Patients were screened from the microbiology laboratory records of all participating centres.
Data collection Baseline characteristics
For each patient, demographic data (age and sex) and predisposing risk factors for LD (smoking, chronic lung or heart disease, diabetes and immunosuppression) were collected.
Clinical features, laboratory data (serum creatinine, AST, ALT, C-reactive protein, white cell and platelet counts, arterial lactate and bicarbonate), radiological findings and severity-of-illness scores [CURB-65, 18 logistic organ dysfunction score (LODS) 19 and SAPS II 20 ] were recorded upon ICU admission.
Antimicrobial strategy
Antimicrobial therapy was considered active against Legionella spp. if it included one of the following classes of antibiotics: macrolides, fluoroquinolones or rifampicin. Two antimicrobial strategies were distinguished according to: (i) the class of antibiotic used within the first 48 h (fluoroquinolone-based versus non-fluoroquinolone-based therapy); and (ii) whether antibiotics were administered in a combined fashion or not (monotherapy versus combination therapy). Combination therapy was defined as the administration of two appropriate antibiotics within the first 2 days of ICU admission and for a duration of at least 3 days (or until death).
Outcome
Outcome variables recorded during ICU stay included the need for mechanical ventilation or renal replacement therapy, the presence of shock and of acute respiratory distress syndrome (ARDS), as stratified according to the Berlin definition, 21 and in-ICU mortality.
Statistical analysis
The data were analysed using the SPSS Base 20.0 statistical software package (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean + SD unless otherwise specified and were compared using Student's t-test or the Mann-Whitney test for independent samples, as appropriate. Categorical variables, expressed as percentages, were evaluated using the v 2 test or Fisher's exact test, as appropriate. Mortality over the follow-up period was analysed using a multivariable Cox model including variables yielding P ,0.10 by univariable analysis, as well as variables previously shown to have a significant relationship with mortality, including age, cancer, a diagnosis of LD not based on urinary antigen test, male gender, previous corticosteroid treatment, and organ failures included in the LODS. 6, 22 Follow-up was censored at date of latest information (i.e. discharge from ICU) or at 60 days, whichever occurred first. For patients who had been admitted to general wards before being admitted to the ICU, the follow-up time (T0) began upon ICU admission. The relationship between the year of inclusion in the study and mortality was assessed by creating a time period variable (2005-10 or 2011-15). In order to reduce confounding when estimating the effects of fluoroquinolone-based therapy on outcome, we performed a propensity score analysis. We matched patients receiving fluoroquinolone-based therapy with those not receiving fluoroquinolonebased therapy, using a greedy matching algorithm with a caliper width of 0.2 standard deviations of the log odds of the estimated propensity score for fluoroquinolone administration and sampling without replacement. We used a graphical representation with absolute standardized differences to check the balance of covariates in the matched sample (see Figure S1 available as Supplementary data at JAC Online). The selection of covariates included in the multivariable logistic regression model used to compute the propensity score of fluoroquinolone-based therapy was guided by their relationship (i.e. P ,0.15) with the use of a fluoroquinolone-based therapy or with death. The final propensity score model included the following 15 covariates: male gender, immunodepression, corticosteroid therapy, HIV infection, smoking, ARDS in the first 24 h of ICU admission, appropriate therapy administered more than 24 h prior to ICU admission, combination therapy regimen, COPD, cirrhosis, age, SAPS II, chronic heart failure, positive urinary antigen and polymicrobial infection. Two-tailed P values ,0.05 were considered statistically significant.
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Results
Study population
During the study period, 249 patients with LD were admitted to the 10 participating ICUs. Of these, 38 patients were excluded because of missing data (n " 13), nosocomial LD (n " 18) or inappropriate antibiotic administration in the first 48 h (n " 7) ( Figure S2 ). Thus, the present study included a total of 211 patients with LD. The baseline characteristics and medical history of these patients are provided in Table 1 . L. pneumophila serogroup 1 strains were involved in 190 patients (92%) ( Table S1 ).
Antimicrobial strategy
Twenty-nine patients (14%) had been receiving an anti-Legionella antibiotic for more than 24 h before ICU admission. All patients but one received an appropriate antimicrobial therapy within the first 24 h following ICU admission. Within 48 h of ICU admission, 49 patients were switched from monotherapy to combined therapy and 50 from non-fluoroquinolone-based to fluoroquinolone-based therapy. After 48 h of ICU admission, another 11 patients were switched to a fluoroquinolone-based treatment. The median time between ICU admission and switching to a fluoroquinolone-based treatment was 4 (3-5) days. In all, a fluoroquinolone-based regimen was administered to 159 patients (75%), mostly in a combined fashion (n " 116, 73%) ( Table 2 and Figure 1) , and a combination therapy was administered to 123 patients and included a fluoroquinolone in most cases (n " 116, 94%). Among cases with dual infections (Table S1 ), the initial antimicrobial therapy adequately covered the associated pathogen for all patients.
Patients' characteristics at baseline and upon ICU admission were not statistically different between groups receiving different antimicrobial strategies, except for a trend towards lower SAPS II in the fluoroquinolone group as compared with the non-fluoroquinolone group (P " 0.05) (Table S2 ) and for fewer patients with haematological malignancies (7% versus 21%; P " 0.002) but more patients with HIV infection (10% versus 1%; P " 0.009) in the combination therapy group as compared with the monotherapy group (Table 1) . Among survivors, the median (IQR) duration of antimicrobial therapy was 21 (14-21) days. Adverse events were reported for 18 patients (9%), and included Clostridium difficile infection (n " 2), drug interactions (n " 2), fluoroquinoloneassociated tendinopathy (n " 1), prolongation of the QT interval (n " 2) complicated by a ventricular tachycardia episode in 1 patient, and immunological hypersensitivity reactions related to rifampicin (n " 5), fluoroquinolones (n " 3) and macrolides (n " 3).
Outcome
During ICU stay, 146 patients (69%) developed ARDS, 111 (53%) developed shock, 56 (27%) developed acute renal failure requiring renal replacement therapy and 54 (26%) died (Table 3 ). The median duration of ICU stay of decedents was 7 (3-23) days. For each antimicrobial strategy, there were no between-group differences regarding the development of organ failures (Table 3) . Nevertheless, in-ICU mortality was lower in the fluoroquinolone group (n " 34, 21%) as compared with the non-fluoroquinolone group (n " 20, 39%; P " 0.01) (see Figure 2a for Kaplan-Meier curves), and in the combination therapy group (n " 24, 20%) as compared with the monotherapy group (n " 30, 34%; P " 0.02). In univariable analysis, risk factors for mortality included a monotherapy regimen, a non-fluoroquinolone-based therapy, an older age, a non-smoking status, previous corticosteroid exposure and a (14) 18 (12) Cecchini et al.
higher severity upon ICU admission (Table 4) . The multivariable Cox model showed that a fluoroquinolone-based, but not a combination therapy, was independently associated with a reduction in the risk of ICU mortality (HR " 0.41, 95% CI 0.19-0.89; P " 0.02). Additional models were used to assess the independent effect estimates of fluoroquinolone-based treatment (Table S3 ) and combination therapy (Table S4 ) on ICU mortality. Of the 52 patients who did not receive a fluoroquinolone-based therapy, 39 (75%) were matched using the propensity score to 39 patients who received a fluoroquinolone (see Table S5 and Figure S2 ). Among the propensity-matched sample, the in-ICU mortalities (95% CI) of patients receiving fluoroquinolone-based versus non-fluoroquinolone-based therapy were 28% (14-42) and 41% (26-56), respectively (P " 0.3) (see Figure 2b for Kaplan-Meier curves of matched samples).
Discussion
The main results of the current observational multicentre retrospective study, which included 211 patients with severe LD Including levofloxacin (n " 109), ofloxacin (n " 41) and ciprofloxacin (n " 9). c Including spiramycin (n " 105), erythromycin (n " 25), azithromycin (n " 7) and roxithromycin (n " 1). Antimicrobial strategy for severe community-acquired legionnaires' disease JAC admitted to the ICU, are as follows: (i) 75% of patients received a fluoroquinolone-based therapy within 48 h of ICU admission, and 73% of these received this antibiotic as part of a combination therapy; (ii) patients who received a fluoroquinolone-based or a combination therapy did not differ significantly from others in terms of severity of illness upon ICU admission; and (iii) a fluoroquinolonebased therapy, but not a combined therapy, was associated with a reduced risk of ICU mortality, after adjustment for other significant covariables-this effect was not confirmed by a propensity-score matched analysis. Several reports have suggested a clinical benefit of fluoroquinolones over macrolides with decreased time to defervescence, reduced length of hospital stay and reduced time to clinical resolution; however, no significant difference in mortality between patients receiving versus those not receiving a fluoroquinolone therapy has previously been conclusively demonstrated. [23] [24] [25] [26] [27] In contrast to mortality rates ranging from ,1% to 6% reported in previous studies assessing the effects of fluoroquinolones in LD, 4, 24, 26, 28 the severe LD cases included in our study had a 26% in-ICU mortality. The high mortality rate of our study reflects the recruitment of critically ill patients with particularly severe forms of LD and likely provides a larger statistical power than in previous observational studies, 4, 24, 26, 28 allowing us to demonstrate a beneficial effect of fluoroquinolone therapy on mortality. Such a protective effect was suggested by the meta-analysis of Burdet et al., 27 which included 12 studies (none of which was a randomized controlled trial) and reported a trend towards a lower mortality rate in patients receiving fluoroquinolones (4.0%) as compared with others (10.9%). However, this trend was not confirmed by the recent study by Gershengorn et al., 28 who used a large US drug utilization database and compared the outcomes of patients (n " 3152) receiving fluoroquinolones or azithromycin, and failed to show a significant benefit of fluoroquinolones on mortality (6.6% versus 6.4%), even in the subgroup of the most severely ill patients (14.9% versus 18.3%). Our study is thus the first one to suggest a beneficial effect on mortality of a fluoroquinolone-based therapy in patients with LD who required ICU admission. These findings support current guidelines, which recommend using fluoroquinolones for the management of severe LD cases. 10, 11 It should be noted that although fluoroquinolones were combined with another antibiotic in 73% of cases, and although the in-ICU mortality of patients receiving a combined therapy was significantly lower than that of others, our multivariable analysis did not show an independent effect of a combined therapy (a fluoroquinolone plus a macrolide in 70% of cases in our study) on mortality. Importantly, we have run several multivariable models in order to account for potential confounders; notably, none of these analyses blunted the significant protective association between fluoroquinolone-based treatment and in-ICU mortality. A sensitivity analysis, in which patients diagnosed with LD more than 48 h after admission (n " 15) were excluded, yielded consistent results (P " 0.06 for the relationship between fluoroquinolone-based treatment and in-ICU mortality in multivariable Cox analysis). The non-significant difference of in-ICU mortality between patients having received fluoroquinolones or not in the propensitymatched cohort analysis mitigates the conclusion that can be drawn regarding an independent effect of fluoroquinolones on mortality. This negative result might be ascribed to the fact that propensity score matching is better than multivariable Cox analysis at taking into account the effect of confounding variables on mortality. However, the results of this analysis should be interpreted with caution given the dramatic reduction in statistical power resulting from propensity score matching (n " 39 patients per group), which limited our ability to confirm a significant effect on mortality. In fact, the number of matched subjects that would have been required to show a significant difference between fluoroquinolone-treated patients and others is twice as high as that included in the current propensity-score matched analysis (69) 93 (59) Cecchini et al.
[i.e. 70 subjects in each group would be required, using a (1 -b) power of 80% and a type 1 error of 0.05].
Our study has a number of limitations. First, this is a retrospective observational study, which included patients managed during a 10 year period, during which quality of care, management of patients and diagnostic procedures might have changed. Also, due to the retrospective design, possible errors in data abstraction might have occurred, and the duration of patient follow-up was limited. Second, although different fluoroquinolones were used by the various participating centres (i.e. levofloxacin, ofloxacin, ciprofloxacin), the small number of patients receiving each drug precluded assessment of their individual effects and, in order to achieve a sufficient statistical power, we had to consider the overall class (i.e. fluoroquinolone) in the final analysis. Thus, the molecule used, the route of administration and its dosing, which might influence antimicrobial efficacy, were not taken into account in the analysis. Nevertheless, we have selected patients based on the timing of appropriate therapy, a factor known to be associated with mortality. 5, 29, 30 Third, because the intravenous formulation of azithromycin is unavailable in France, only a few patients were treated with this macrolide, making it difficult to compare our results with other studies. 28 Fourth, as performed in previous studies, 27 we have chosen to include in the analysis patients for whom the diagnosis of legionellosis relied solely on a positive PCR (n " 4), which the ECDC categorizes as probable cases, 1 because these patients were eventually managed as LD cases by clinicians. Last, because assignment to a treatment group (i.e. combination therapy or not and fluoroquinolone-based therapy or not) was made after patients entered the study (i.e. ICU admission), there is a theoretical risk of so-called immortal time bias, according to which immortal Antimicrobial strategy for severe community-acquired legionnaires' disease JAC time, i.e. patient days preceding assignment to a treatment category, is either misclassified (i.e. systematically attributed to the treated groups) or excluded from analysis. 31 The fact that only patients receiving adequate treatment within 48 h of ICU admission were included in this study likely reduced the risk for such bias to yield a significant confounding effect.
In conclusion, the results of this retrospective observational multicentre study suggest that patients with severe LD might benefit from a fluoroquinolone-based antimicrobial regimen in the early stages of management in the ICU. Our results do not support an additional effect of combination therapy over monotherapy. A propensity-score matched analysis did not provide adequate power to confirm the benefit of fluoroquinolone-based therapy on in-ICU mortality.
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